PNC Financial Services Group Inc. Cuts Position in Solventum Corporation $SOLV

Posted by Francis Steltz on May 24th, 2026

PNC Financial Services Group Inc. cut its stake in Solventum Corporation (NYSE:SOLV – Free Report) by 8.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 157,848 shares of the company’s stock after selling 14,523 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Solventum were worth $12,508,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in SOLV. Hilltop National Bank increased its holdings in shares of Solventum by 71.3% in the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after acquiring an additional 129 shares during the period. Measured Wealth Private Client Group LLC purchased a new position in shares of Solventum in the 3rd quarter valued at $25,000. Deseret Mutual Benefit Administrators increased its holdings in shares of Solventum by 78.7% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock valued at $27,000 after acquiring an additional 163 shares during the period. JNBA Financial Advisors increased its holdings in shares of Solventum by 205.4% in the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after acquiring an additional 228 shares during the period. Finally, CYBER HORNET ETFs LLC purchased a new position in shares of Solventum in the 2nd quarter valued at $28,000.

Solventum Trading Up 0.2%

Shares of Solventum stock opened at $76.92 on Friday. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96. Solventum Corporation has a 12-month low of $62.38 and a 12-month high of $88.20. The firm has a market capitalization of $13.32 billion, a price-to-earnings ratio of 9.43, a PEG ratio of 1.19 and a beta of 0.59. The firm’s 50 day simple moving average is $68.68 and its two-hundred day simple moving average is $74.77.

Solventum (NYSE:SOLV – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.35 by $0.13. The business had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. Solventum’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Analysts predict that Solventum Corporation will post 6.57 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on SOLV. KeyCorp boosted their target price on Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. BTIG Research restated a “buy” rating and set a $89.00 target price on shares of Solventum in a research note on Wednesday, May 6th. Stifel Nicolaus dropped their target price on Solventum from $105.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Wedbush began coverage on Solventum in a research note on Friday, May 15th. They set an “outperform” rating and a $94.00 target price on the stock. Finally, Wells Fargo & Company dropped their target price on Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 6th. Eight analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Solventum has an average rating of “Moderate Buy” and an average price target of $84.25.

Get Our Latest Stock Analysis on Solventum

Insiders Place Their Bets

In other news, Director Amy Mcbride Wendell purchased 1,475 shares of the company’s stock in a transaction on Tuesday, March 10th. The shares were acquired at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the purchase, the director owned 5,039 shares in the company, valued at $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.24% of the company’s stock.

Solventum Profile

(Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.